LCT expands diabetes trial
Friday, 06 June, 2008
Living Cell Technologies (ASX: LCT) has decided to begin testing larger doses in its phase 1 clinical trial for type 1 diabetes.
In phase one of the trial, five patients were implanted with the lowest recommended dose of the company's DiabeCells, encapsulated insulin-producing cells sourced from pigs.
So far the patients have experienced no ill-effects, and have experienced a quantifiable reduction in the amount of insulin they require daily.
Both the number of patients and the dosage they receive has been doubled over the previous trial, with 10 patients receiving the double dose.
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
